ArticleFrontiers in immunology2025
Development of a novel prognostic score for 1-year survival in immunotherapy-treated patients with unresectable HCC: the ALIVE-IO score.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is a lack in reliable and widely used prognostic scores to predict survival in patients with hepatocellular carcinoma (HCC) receiving immunotherapy. The aim of our study was to develop a prognostic score that could predict 1-year OS in patients with unresectable HCC receiving immunotherapy. Methods: We studied 100 patients who received 1 Results: In univariate analysis, significant correlation with OS was found for ALBI grade (p<0.001, HR=2.725), BCLC stage (p=0.031, HR=1.809), macrovascular invasion (p<0.001, HR=2.587), up-to-7 criteria (p<0.001, HR=0.218) and lymphocyte infiltration (p=0.005, HR=0.485). In the multivariate analysis, three factors were significantly correlated with OS; ALBI grade (grade II vs. I, p=0.025, HR=1.946), up-to-7 criteria (beyond vs. within, p=0.001, HR=3.506) and lymphocyte infiltration (no vs. yes, p=0.016, HR=1.889). The ALIVE-IO score was calculated with the contribution of 1 point for ALBI grade II, 2 points for exceeding up-to-7 criteria and 1 point for absence of lymphocyte infiltration. The score had an AUROC of 0.755 for 1-year OS, with 75% sensitivity and 65.4% specificity. We established three risk groups; low (ALIVE-IO: 0-1), intermediate (ALIVE-IO: 2-3) and high (ALIVE-IO: 4). Objective response was reported in 34.8% of patients in the low risk group, compared to 18.5% in intermediate and 4.3% in high risk patients (p=0.031). The median OS of the three groups was 41, 12 and 3 months, respectively (p<0.001). The 1-year OS was 80%, 41% and 16, respectively. Conclusion: The ALIVE-IO score is a promising tool for predicting 1-year OS in HCC patients undergoing immunotherapy using common laboratory, imaging and histological data frequently used in everyday clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.